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	 A	 comparative	 and	 stability‐indicating	 reversed	 phase	 high	 performance	 liquid
chromatographic	 study	 have	 been	 developed	 and	 validated	 for	 sitagliptin	 phosphate.	 The
liquid	 chromatographic	 determination	 was	 achieved	 isocratically	 on	 Poroshell	 120	 EC‐C18
(100	×	4.6	mm,	i.d.;	particle	size,	2.7	µm),	Pursuit	5PFP	(150	×	4.6	mm,	i.d.;	particle	size,	5	µm)
and	Chromolith	performance	RP‐18e	(100	×	4.6	mm,	i.d.;	macropore	diameter,	2	µm)	columns
using	 a	mobile	 phase	 consisting	 of	 methanol:water:triethylamine:acetic	 acid	 (60:40:0.1:0.1;
v:v:v:v),	at	a	 flow	rate	0.5	mL/min	and	UV	detection	at	268	nm.	The	method	was	linear	over
the	 concentration	 range	 of	 100‐1000	 µg/mL	 (r	 =	 0.9998)	 with	 a	 limit	 of	 detection	 and
quantitation	 of	 10	 and	 30	 µg/mL,	 respectively.	 All	 the	 validation	 parameters	 and	 stability
indicating	 study	 were	 studied	 on	 Poroshell	 120	 EC‐C18	 column,	 which	 achieved	 the	 best
separation.	The	proposed	method	has	been	 found	to	have	the	required	accuracy,	 selectivity,
sensitivity,	and	precision	to	assay	sitagliptin	phosphate	in	bulk	form	and	in	a	pharmaceutical
dosage	form.	Degradation	products	resulting	from	the	stress	studies	did	not	interfere	with	the
detection	of	sitagliptin	phosphate	that	indicates	that	the	assay	are	stability‐indicating	assay.	
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1.	Introduction	
	
Sitagliptin	 phosphate	 (STG)	 [1‐4]	 is	 1,2,4‐triazolo	 [4,3‐a]	
pyrazine,7‐[(3R)‐3‐amino‐1‐oxo‐4‐(2,4,5‐trifluorophenyl)	
butyl]‐5,6,7,8‐tetra‐hydro‐3‐(trifluoromethyl)	 phosphate	
(Figure	 1).	 It	 is	 the	 first	 dipeptidylpeptidase‐4	 inhibitor	 to	 be	
used	in	the	management	of	type	2	diabetes.	It	is	widely	used	as	
an	add‐on	therapy	to	ongoing	management	or	as	monotherapy	
when	it	is	deemed	necessary.	It	has	been	found	to	be	beneficial	
in	improving	β‐cell	function	and	glycemic	control.	Moreover,	in	
special	 circumstances	 like	 chronic	 kidney	 disease	 it	 is	 used	
with	appropriate	dose	reductions	[5].	
Literature	survey	revealed	that	some	LC‐MS	methods	[6‐9]	
were	reported	for	the	determination	of	sitagliptin	phosphate	in	
plasma	and	urine	of	humans,	rats	and	dogs.	Also,	spectrophoto‐
metric	 techniques	 were	 used	 for	 the	 determination	 of	
sitagliptin	and	characterized	by	their	simplicity,	specificity	and	
low	 cost	 [10,11].	 In	 addition,	 some	 analytical	 methods	 were	
used	for	the	validation	and	estimation	of	sitagliptin	in	bulk	and	
pharmaceutical	 formulations	 [12‐14].	 This	 study	 presents	 a	
comparative	 determination	 of	 sitagliptin	 phosphate	 on	 three	
different	 stationary	 phases,	 Poroshell	 120	 EC‐C18,	 Pursuit	
5PFP	 and	 Chromolith	 Performance	 RP‐18e	 column.	 All	 the	
validation	 parameters	 and	 stability‐indicating	 study	 will	 be	
studied	on	the	column,	which	achieves	the	best	determination	
of	 sitagliptin	 phosphate	 in	 bulk	 and	 pharmaceutical	 formula‐
tions.	
	
	
	
Figure	1. Sitagliptin	phosphate.	
	
2.	Experimental	
	
2.1.	Chemicals	and	reagents	
	
Sitagliptin	phosphate	 standard	bulk	 powder	was	obtained	
from	Merck	Sharp	&	Dohme	Ltd.,	Cramlington	Northumberland	
and	was	used	as	received,	certified	to	be	99.80%	pure.	Januvia	
100	mg,	50	mg	and	25	mg	(Labeled	to	contain	100	mg,	50	mg	
and	25	mg	 of	 sitagliptin	phosphate	 per	 tablet)	were	 obtained	
from	 the	 Merck	 Sharp	 &	 Dohme	 Ltd.,	 Cramlington,	 UK	
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(Imported	 by	 SoficoPharm,	 Cairo,	 Egypt).	 Methanol,	 triethyl	
amine,	 acetic	 acid	 were	 obtained	 from	 Merck	 (Darmstadt,	
Germany).	 All	 chemicals	 were	 of	 analytical	 grade.	 Purified	
HPLC	 grade	 water	 was	 obtained	 by	 reverse	 osmosis	 and	
filtration	 through	 a	 Milli‐Q	 system	 (Millipore,	 Milfored,	 MA,	
USA)	and	was	used	as	a	mobile	phase.	
	
2.2.	Instrumentation	and	conditions	
	
The	 HPLC	 unit	 was	 an	 Agilent	 1100	 series	 apparatus	
equipped	 with	 a	 quaternary	 pump,	 a	 vacuum	 degasser,	 a	
column	 oven,	 a	 diode	 array	 UV‐detector	 and	 HP	 Chemstation	
for	LC	3D	systems	B.0301	[317]	software.	Three	columns	were	
used	in	this	study	namely	(100	×	4.6	mm,	i.d.;	particle	size,	2.7	
µm),	Pursuit	5PFP	(150	×	4.6	mm,	i.d.;	particle	size,	5	µm)	were	
purchased	 from	Agilent	Technologies	and	 (100	×	4.6	mm,	 i.d.;	
macropore	 diameter,	 2	 µm)	 was	 from	 Merck	 (Darmstadt,	
Germany).	 Separation	 was	 achieved	 using	 a	 mobile	 phase	
consisting	 of	methanol:water:triethylamine:acetic	 acid	 (60:40:	
0.1:0.1;	 v:v:v:v),	 at	 a	 flow	 rate	 0.5	 mL/min.	 The	 column	 was	
maintained	 at	 temperature	 20	 °C	 and	 UV	 268	 nm	 and	 an	
injection	 volume	 of	 5	 µL	 was	 used.	 The	 mobile	 phase	 was	
filtered	 through	 0.45	 µm	 chromTech	 Nylon‐66	 filter	 and	
degassed	 in	 an	 ultrasonic	 bath.	 For	 analysis	 of	 forced	
degradation	samples,	 the	photodiode	array	detector	was	used	
in	scan	mode	with	a	scan	range	of	200‐500	nm.		
	
2.3.	Statistical	analysis	
	
Linear	 regression	 of	 the	 data	 was	 performed	 by	 using	
statistical	package	for	social	science	(SPSS)	program	version	16	
software	(SPSS	Inc.,	U.S.A.).	The	level	of	significance	was	set	at	p	
≤	0.05.	
	
2.4.	Preparation	of	stock	and	standard	solutions	
	
A	 stock	 solution	 of	 sitagliptin	 phosphate	 (1	 mg/mL)	 was	
prepared	 in	 HPLC‐grade	 methanol.	 The	 stock	 solution	 was	
protected	from	light	using	aluminum	foil	and	stored	for	1	week	
at	 4	 °C,	 and	was	 found	 to	 be	 stable	 during	 this	 period.	 In	 the	
HPLC	 assay,	 aliquots	 of	 the	 standard	 stock	 solution	 of	
sitagliptin	 phosphate	 were	 transferred	 using	 grade	 bulb	
pipettes	into	10	mL	volumetric	flasks.	The	solutions	were	made	
up	to	volume	with	methanol	to	give	final	concentrations	of	100,	
150,	 200,	 300,	 500,	 800	 and	 1000	 µg/mL,	 using	 external	
standard	(1000	µg/mL).	
	
2.5.	Preparation	of	tablets	for	assay	
	
Ten	 tablets	were	weighed	and	ground	 to	a	 fine	powder.	A	
portion	 of	 the	 powdered	 tablets	 equivalent	 to	 100	 mg	 was	
accurately	weighed	 into	100	mL‐A	grade	volumetric	 flask	and	
30	mL	methanol	was	added.	The	volumetric	flask	was	sonicated	
for	 20	 min	 to	 ensure	 complete	 dissolution	 of	 the	 sitagliptin	
phosphate	 then	 the	solution	was	made	up	 to	 the	volume	with	
methanol.	Suitable	aliquots	of	solution	were	filtered	through	a	
0.45	 µm	 nylon	 filter	 and	 completed	 as	 previously	 mentioned	
under	preparation	of	stock	and	standard	solution	for	HPLC.	
	
2.6.	Forced	degradation	studies	of	authentic	sitagliptin	
phosphate	and	its	tablet	formulation	
	
In	 order	 to	 determine	 whether	 the	 proposed	 analytic	
method	 is	 stability‐indicating,	 sitagliptin	 phosphate	 in	 its	
tablets	pharmaceutical	dosage	 form	and	powder	was	stressed	
under	 various	 conditions	 to	 conduct	 forced	 degradation	
studies.	Regulatory	guidance	in	ICH,	Q2A,	Q2B,	Q3B	and	FDA	21	
CFR	 section	 211	 require	 the	 development	 and	 validations	 of	
stability	indicating	potency	assays	[15].	
	
	
2.6.1.	Oxidation		
	
Solutions	for	oxidation	studies	were	prepared	by	dissolving	
100	mg	of	standard	sitagliptin	phosphate	and	powdered	tablets	
containing	an	equivalent	to	100	mg	of	sitagliptin	phosphate	in	
methanol	and	3%	H2O2	(20:80%;	v:v:),	protected	from	light	and	
stored	at	room	temperature	for	3	days.		
	
2.6.2.	Acid	degradation	studies	
	
Solutions	 for	 acid	 degradation	 studies	 were	 achieved	 by	
refluxing	 100	 mg	 of	 standard	 sitagliptin	 phosphate	 and	
powdered	 tablets	 containing	 an	 equivalent	 to	 100	 mg	 of	
sitagliptin	phosphate	 in	2	M	hydrochloric	acid	at	100	°C	 in	an	
oil	 bath	 for	 24	hr.	 The	 reaction	mixture	was	neutralized	with	
a~2.5	 M	 sodium	 hydroxide	 and	 extracted	 with	 ethyl	 acetate,	
dried	(Na2SO4	anhydrous)	and	evaporated	under	vacuum.	The	
residue	was	dissolved	in	methanol	(100	mL).		
	
2.6.3.	Alkali	degradation	studies	
	
Solutions	for	alkali	degradation	studies	were	performed	by	
refluxing	100	mg	standard	sitagliptin	phosphate	and	powdered	
tablets	 containing	 an	 equivalent	 to	 100	 mg	 of	 sitagliptin	
phosphate	in	1	M	sodium	hydroxide	at	100	°C	in	an	oil	bath	for	
24	 hr.	 The	 reaction	mixture	was	 then	 diluted	with	water	 and	
extracted	 with	 ethyl	 acetate,	 dried	 (Na2SO4	 anhydrous)	 and	
evaporated	 under	 vacuum.	 The	 residue	 was	 dissolved	 in	
methanol	(100	mL).	
	
2.6.4.	Neutral	degradation	studies	
	
Solutions	for	neutral	degradation	studies	were	prepared	by	
dissolving	 100	 mg	 standard	 sitagliptin	 phosphate	 and	
powdered	 tablets	 containing	 an	 equivalent	 to	 100	 mg	 of	
sitagliptin	 phosphate	 in	 methanol	 and	 water	 (20:80,	 v:v),	
protected	 from	 light,	 and	 stored	 at	 room	 temperature	 for	 3	
days.	
	
2.6.5.	Temperature	stress	studies	
	
Standard	 sitagliptin	 phosphate	 and	 its	 powdered	 tablets	
were	exposed	to	dry	heat	(90	°C)	in	an	oven	for	3	days.	
	
2.6.6.	Photostability	degradation	assay	
	
Bulk	 sitagliptin	 phosphate	 powder,	 its	 powdered	 tablets,	
and	 their	 methanolic	 solutions	 were	 exposed	 to	 light	 to	
determine	the	effect	of	irradiation	on	the	stability	of	sitagliptin	
phosphate	 in	 the	 solid	 state	 and	 in	 the	 solution	 form.	
Approximately,	 100	 mg	 of	 standard	 sitagliptin	 phosphate	
powders	were	 spread	 on	 a	 glass	dish	 in	 a	 layer	 that	was	 less	
than	 2	 mm	 in	 thickness.	 Solutions	 of	 standard	 sitagliptin	
phosphate	(1	mg/mL)	were	prepared	in	methanol.	All	samples	
for	 photostability	 testing	 were	 placed	 in	 a	 light	 cabinet	
(Thermolab,	India)	and	exposed	to	light	for	40	h	resulting	in	an	
overall	illumination	≥200	wh/m2	at	25	°C	with	UV‐radiation	at	
320‐400	nm.	Control	samples,	which	were	protected	from	light	
with	 aluminum	 foil,	were	 also	 placed	 in	 the	 light	 cabinet	 and	
exposed	 concurrently	 following	 the	 removal	 from	 the	 light	
cabinet.	
	
3.	Results	and	discussion	
	
3.1.	HPLC	method	development	and	optimization	
	
Poroshell	 120	 EC‐C18	 (100	 ×	 4.6	 mm,	 i.d.),	 Pursuit	 5PFP	
(150	×	4.6	mm,	i.d.)	and	Chromolith	Performance	RP‐18e	(100	
×	 4.6	 mm)	 columns	 were	 used	 for	 the	 determination	 of	
sitagliptin	phosphate.		
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Table	1	Comparative	chromatographic	and	validation	parameters	of	sitagliptin	using	different	stationary	phases	
Parameter	 Poroshell	120	EC‐C18	Column	 Chromolith	performance	RP‐18e	Column	 Pursuit	5PFP	Column	
Regression	equation,	r2	 y	=	0.0010x‐0.008,	0.999 y	=	0.0010x‐0.010,	0.999 	y	=	0.0010x‐0.014,	0.999
Capacity	factor	(k`)	 0.399	 0.200 0.696	
Time	of	analysis	(min)	 10.000	 10.000 10.000	
Retention	time	(min)	 2.629	 3.418 5.713	
No.	of	theoretical	plates	(N)	 8794.286	 4673.200	 19130.824	
No.	of	theoretical	plates/mm	 87.94286	 46.73200	 12.75388	
Tailing	factor	 2.5	 1.4 2	
Asymmetry	factor	 3	 2	 3	
Linearity	(µg/mL)	 100‐1000		 100‐1000	 100‐1000	
Sensitivity	(µg/mL)	 100	 100 100	
Precision	
Repeatability	
(Intraday)	
1.23	
0.99	
0.62	
‐
‐	
‐	
‐	
‐	
‐	
Intermediate	precision		
(Interday)	
1.60	
1.20	
0.99	
‐
‐	
‐
‐	
‐	
‐	
Accuracy	 1.23	
0.82	
0.63	
‐	
‐	
‐	
‐	
‐	
‐	
Selectivity	 1.34	 1.20 1.30	
L.O.D.	(µg/mL)	 10		 ‐ ‐	
L.O.Q.	(µg/mL)	 30	 ‐ ‐	
	
	
Calibration	 curves,	 correlation	 coefficient,	 slope,	 intercept,	
capacity	 factor,	 retention	 time,	 number	 of	 theoretical	 plates,	
number	of	theoretical	plates/mm,	tailing	factor	and	asymmetry	
factors	 were	 determined	 using	 the	 previously	 mentioned	
columns	as	shown	in	Table	1.	It	was	that	Poroshell	120	EC‐C18	
has	 achieved	 the	 best	 separation	 due	 to	 it	 has	 the	 highest	
number	of	theoretical	plates/mm	so	it	was	chosen	to	study	all	
the	 validation	 parameters.	 The	method	was	 validated	 for	 the	
determination	of	sitagliptin	phosphate	 in	bulk	and	 in	pharma‐
ceutical	 dosage	 form.	 The	 stressed	 samples	 were	 initially	
analyzed	using	 a	mobile	 phase	 consisting	 of	methanol:	water:	
triethylamine:acetic	acid	(60:40:0.1:0.1;	v:v:v:v)	which	achieved	
better	separation	without	tailing	at	a	flow	rate	of	0.5	mL/	min	
and	 UV	 detection	 at	 268	 nm	 using	 1000	 µg/mL	 sitagliptin	
phosphate	as	an	external	standard.	
	
3.2.	Validation	
	
The	 method	 was	 validated	 with	 respect	 to	 parameters	
including	 linearity,	 limit	 of	 quantitation	 (LOQ),	 Limit	 of	
detection	 (LOD),	 precision,	 accuracy,	 selectivity	 and	 recovery	
using	Poroshell	120	EC‐C18.	
	
3.2.1.	Linearity	
	
The	 calibration	 curves	 constructed	 for	 sitagliptin	
phosphate	were	linear	over	the	concentration	range	100‐1000	
µg/mL.	Peak	areas	of	sitagliptin	phosphate	were	plotted	versus	
its	concentration	and	linear	regression	analysis	was	performed	
on	the	resultant	curve.	
		
3.2.2.	Limit	of	quantitation	(LOQ)	and	limit	of	detection	
(LOD)	
	
The	 LOQ	 and	 LOD	 were	 determined	 based	 on	 signal	 to	
noise	 ratios.	 The	 LOQ	 was	 found	 to	 be	 30	 µg/mL	 with	 a	
resultant	%.R.S.D	of	0.4%	(n	=	5),	where	the	LOD	was	found	to	
be	10	µg/mL.	
	
3.2.3.	Precision	
	
Precision	of	the	assay	was	investigated	with	respect	to	both	
repeatability	 and	 reproducibility.	 Repeatability	 was	
investigated	by	 injecting	nine	 replicate	samples	of	each	of	 the	
200,	400	and	600µg/mL	where	the	mean	concentrations	were	
found	to	be	199.81,	400.23	and	598.40	with	associated	relative	
standard	 deviation	 (%	 R.S.D.)	 values	 of	 1.23,	 0.99	 and	 0.62,	
respectively.	 Inter‐day	precision	was	assessed	by	 injecting	the	
same	three	concentrations	over	3	consecutive	days,	resulting	in	
mean	concentrations	of	sitagliptin	phosphate	of	200.30,	400.48	
and	 600.22	 µg/mL	 and	 associated	 %	 R.S.D	 of	 1.60,	 1.20	 and	
0.99	%,	respectively.		
	
3.2.4.	Accuracy	
	
Accuracy	 of	 the	 assay	was	 determined	 by	 interpolation	 of	
replicate	 (n	 =	 6)	 peak	 area	 of	 three	 accuracy	 standards	 (200,	
400	 and	 600	 µg/mL)	 from	 a	 calibration	 curve	 prepared	 as	
previously	 described.	 In	 each	 case	 the	 percent	 relevant	 error	
was	calculated.	The	resultant	concentration,	were	199.62±0.81	
µg/mL,	 (mean±S.D.),	 400.34±0.56	 µg/mL	 and	 600.52±0.41	
µg/mL	 with	 percent	 relevant	 errors	 of	 1.23,	 0.82	 and	 0.63,	
respectively.	
	
3.2.5.	Selectivity	
	
The	 results	 of	 stress	 testing	 studies	 were	 performed	 on	
Poroshell	120	EC‐C18	and	showed	a	high	degree	of	selectivity	
of	 this	 method	 for	 sitagliptin	 phosphate.	 The	 degradation	 of	
sitagliptin	 phosphate	 was	 found	 to	 be	 similar	 for	 both	 the	
tablets	 and	 bulk	 powder.	 Typical	 chromatograms	 obtained	
following	 the	assay	of	pure	bulk	 sample	and	stressed	samples	
are	shown	in	Figure	2‐4.	
Figure	3	showed	 that	sitagliptin	was	completely	degraded	
by	hydrogen	peroxide	with	the	appearance	of	two	degradation	
products	 at	 retention	 time	 1.987	 and	 7.429	 min.	 Also,	
sitagliptin	 was	 partially	 degraded	 by	 alkaline	 condition	 and	
showed	three	degradation	products	at	1.921,	6.535	and	7.430	
min,	 while	 the	 acidic	 condition	 led	 to	 partial	 degradation	 of	
sitagliptin	with	the	formation	of	several	degradation	products.	
	
	
	
Figure	2.	Typical	 chromatogram	of	 sitagliptin	 phosphate	 on	Poroshell	 120	
EC‐C18	column.	
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(a)	
	
	
(b)	
	
(c)	
	
Figure	 3.	 Degradation	 products	 of	 sitagliptin	 phosphate	 on	 Poroshell	 120	
EC‐C18	 column.	 (a)	 Hydrogen	 peroxide	 degradation	 products,	 (b)	 Alkaline	
degradation	products,	and	(c)	Acidic	degradation	products.	
	
	
	
	
Figure	 4.	 Lab	 mixture	 of	 sitagliptine	 and	 hydrogen	 peroxide	 degradation	
products	on	Poroshell	120	EC‐C18	column.	
	
	
3.2.6.	Recovery	
	
A	 known	 amount	 of	 sitagliptin	 phosphate	 standard	 bulk	
powder	 was	 added	 to	 aliquots	 (n	 =	 20)	 of	 tablet	 contents,	
mixed,	 and	 the	 powder	 was	 extracted	 and	 diluted	 to	 yield	 a	
starting	 concentration.	 This	 solution	 was	 analyzed	 and	 the	
assay	was	 repeated	 (n	=	9)	over	3	 consecutive	days	 to	obtain	
intermediate	 precision	 data.	 The	 observed	 concentration	 of	
sitagliptin	 phosphate	 was	 found	 to	 be	 300.00±0.42	 µg/mL	
(mean±S.D).	The	resultant	%	R.S.D.	for	this	study	was	found	to	
be	0.418%	with	a	corresponding	percentage	recovery	value	of	
100.44%.		
	
3.3.	Assay	
	
The	proposed	method	was	applied	for	the	determination	of	
sitagliptin	phosphate	 in	 the	 tablet	 formulations.	The	results	of	
these	 assays	 yielded	 100.60%	 (%	R.S.D	 =	 1.62%)	 of	 expected	
amount	of	the	tablets.	These	results	indicated	that	the	method	
is	 selective	 for	 the	 assay	 of	 sitagliptin	 phosphates	 without	
interference	the	excipient	used	in	those	dosage	forms.		
	
3.4.	Stability	studies	
	
All	 stressed	 samples	 in	 both	 solid	 states	 and	 in	 solution	
forms	 remained	 colorless.	No	decomposition	was	 observed	 in	
neutral	 medium	 and	 on	 exposure	 of	 sitagliptin	 phosphate	 in	
solid	 states	 and	 in	 solution	 forms	 to	 light	 in	 a	 photo	 stability	
chamber	at	room	temperature.	On	the	other	hand,	it	was	found	
that	sitagliptin	had	been	extensively	degraded	on	treating	with	
3%	 hydrogen	 peroxide	 for	 3	 days.	 The	 retention	 time	 Rt	 of	
hydrogen	 peroxide	 degradation	 products	 of	 sitagliptin	
phosphate	were	1.987	and	7.429	min.	Also	76	and	28%	degra‐
dation	was	observed	in	alkaline	and	acidic	media,	respectively,	
as	shown	in	Figure	3	and	4.		
	
3.4.1.	Stability‐indicating	method	for	analysis	of	sitagliptin	
phosphate	in	presence	of	its	hydrogen	peroxide	‐oxidative	
degraded	products	by	HPLC	
	
A	 simple	HPLC	method	was	 adopted	 for	 the	 simultaneous	
determination	 of	 sitagliptin	 phosphate	 and	 its	 oxidative	
hydrogen	 peroxide	 degraded	 products	 in	 bulk	 powder.	 To	
optimize	 the	 proposed	 HPLC	method,	 all	 of	 the	 experimental	
conditions	were	 investigated.	 To	 optimize	 the	mobile	 phases,	
different	systems	were	tried	for	chromatographic	separation	of	
the	 two	 components	 by	 combining	 homogenous	 design	 and	
solvent	polarity	optimization.	The	best	resolution	was	achieved	
using	 a	 mobile	 phase	 consisting	 of	 methanol:water:triethyl	
amine:acetic	acid	(60:40:0.1:0.1;	v:v:v:v)	which	gave	good	reso‐
lution	 and	 sensitivity	 of	 all	 components.	 A	 linear	 relationship	
was	 obtained	 between	 peak	 area	 and	 the	 concentration	 of	
sitagliptin	phosphate	 in	the	presence	of	 its	hydrogen	peroxide	
oxidative	degraded	products	 in	the	range	of	100‐1000	µg/mL.	
The	linear	regression	equation	was	computed	as:		
	
y	=	0.0010x+	0.0033	 r	=	0.9998	 	 (1)	
	
where	 y	 is	 the	 area	 under	 the	 peak,	 x	 is	 the	 concentration	 in	
µg/mL,	and	r	is	a	correlation	coefficient.	
The	 results	 obtained	 by	 applying	 the	 HPLC	 procedure	
showed	 that	 sitagliptin	 phosphate	 can	 be	 simultaneously	
analyzed	 in	 the	 presence	 of	 its	 hydrogen	 peroxide	 oxidative	
degraded	with	mean	recoveries	of	100.05±1.399%,	Table	2.		
The	 proposed	 method	 has	 been	 applied	 to	 the	 assay	 of	
sitagliptin	phosphate	in	its	tablet	form	without	any	interference	
from	 the	 excipients.	 The	 validity	 of	 the	 suggested	 procedure	
was	 further	 assessed	 by	 applying	 the	 standard	 addition	
technique	with	mean	recoveries	100.48±0.692%,	Table	3.	
A	 statistical	 comparison	 of	 the	 results	 obtained	 by	 the	
proposed	HPLC	method	and	the	Clarke	procedure	that	depends	
on	 UV	 spectrophotometric	 determinations	 of	 sitagliptin	
phosphate	 [16]	 in	 a	 pure	 drug	 are	 shown	 in	 Table	 4.	 The	
calculated	 t	 and	 F	 values	were	 less	 than	 the	 tabulated	 values	
[17],	which	revealed	that	there	is	no	significant	difference	with	
respect	to	accuracy	and	precision	determined	through	assay	of	
variables.	 Also,	 some	 statistical	 analysis	 was	 studied	 such	 as	
linear	regression	parameters	as	shown	in	Table	5	and	6.	
Blind	 samples	 of	 pure	 sitagliptin	 phosphate	 of	 different	
concentrations	were	calculated	from	its	regression	equation.		
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Table	2.	Determination	of	pure	bulk	sitagliptin	phosphate	by	HPLC.	
Mixture	no	 Concentration	taken	(µg/mL)	 Found	(µg/mL)	 Found	(%)	
1	 150.00	 151.70 101.13	
2	 300.00	 294.70 98.23	
3	 500.00	 508.70 101.74	
4	 800.00	 795.70 99.46	
5	 1000.00	 996.70	 99.67	
Mean	±	S.D	 	 	 100.05±1.399	
	
	 	 	 	 	 	 	 	 	
Table	3.	Application	the	standard	addition	technique	to	the	analysis	of	sitagliptin	phosphate	by	HPLC	in	its	tablet	dosage	form.	
Product	 Found	(%)	 Pure	added	(µg/mL)	 Found		(µg/mL)	 Recovery	(%)	
Januvia	100	mg	Sitagliptin	phosphate/Tablet	 100.60±1.62 100.00 101.20 101.20
200.00 199.10 99.55
300.00 302.30 100.77
400.00 403.60 100.90
500.00 499.80 99.96
Mean	±	S.D	 	 100.48±0.69
	
	
Table	4.	Statistical	analysis	of	the	results	obtained	by	applying	the	proposed	UV	spectrophotometric	method	[16]	for	the	analysis	of	pure	sitagliptin	phosphate.		
Parameter	 Proposed	HPLC	method	 UV	spectrophotometric	method	
Mean	±S.D	 100.05±1.399	 99.88±0.899
na	 5	 5
t	 0.251	(2.306)	b 	 ‐
F	 2.422	(6.390)	b ‐
a	n:	Number	of	determinations.	
b	The	values	in	parentheses	are	corresponding	to	the	theoretical	values	of	t	and	F	at	(p	=	0.05).	
	
	
Table	5.	Linear	regression	data,	ANOVA	a	of	regression.	
Model	 	 Sum	of	squares	 df	 Mean	square	 F	 Sigma	
Mixture	no:	1	 Regression	 0.720	 1 0.720 11335.665	 0.000	b
Residual	 0.000	 5 0.000
Total	 0.720	 6	 	 	 	
a	Dependent	Variable:	Area.	
b	Predictors:	(Constant),	Conc.	µg/mL.	
	
	
Table	6.	Linear	regression	data,	coefficients	a.	
Model	 Unstandardized	coefficients	 Standardized	coefficients	 t	 Sigma	 95%	Confidence	interval	for	B	
B	 Standard	error	 Beta	 Lower	bound	 Upper	bound	
Mixture	no:	1	 Constant	 0.003	 0.005	 0.658 0.539 ‐0.010	 0.016
Conc.	µg/mL	 0.001	 0.000	 1.000 106.469 0.000 0.001	 0.001
a	Dependent	Variable:	Area.	
	
	
The	 degree	 of	method	 repeatability	 (intra‐day)	 and	 inter‐
mediate	 precision	 (inter‐days)	 were	 measured	 by	 analysing	
each	 concentration	 of	 sitagliptin	 phosphate	 four	 times	 by	 the	
proposed	 method	 in	 the	 same	 day	 and	 for	 four	 days,	 then	
calculating	 %R.S.D.	 values	 which	 were	 0.53	 and	 0.74,	
respectively.	The	results	of	the	proposed	method	showed	that	it	
is	 accurate,	 precise,	 specific,	 and	 rugged	 according	 to	 the	
%R.S.D.	values	of	intra‐day	and	inter‐day	determinations.	
	
4.	Conclusion	
	
A	validated	stability‐indicating	HPLC	analytical	method	has	
been	developed	for	 the	determination	of	sitagliptin	phosphate	
in	pure	form	and	in	tablet	dosage	formulation.	All	the	validation	
parameters	 were	 studied	 on	 Poroshell	 120	 EC‐C18	 column	
which	achieved	the	best	separation.	The	results	of	stress	testing	
were	under	taken	according	to	the	international	conference	on	
harmonization	 (ICH)	 guidelines,	 which	 revealed	 that	 the	
studied	method	is	selective	and	stability‐indicating.	The	propo‐
sed	 method	 has	 been	 found	 to	 have	 the	 required	 accuracy,	
selectivity,	 sensitivity,	 and	 precision	 to	 assay	 sitagliptin	
phosphate	 in	bulk	 form	and	 in	 a	pharmaceutical	dosage	 form.	
Degradation	products	resulting	from	the	stress	studies	and	the	
excipients	 found	 in	 the	 tablet	 dosage	 forms	 did	 not	 interfere	
with	the	detection	of	sitagliptin	phosphate	which	indicates	that	
the	assay	are	stability‐indicating	assay.	The	achieved	methods	
are	suitable	for	the	routine	analysis	of	sitagliptin	phosphate	in	
either	 bulk	 powder	 or	 in	 pharma‐ceutical	 dosage	 forms.	 The	
simplicity	 of	 the	 applied	 method	 allows	 their	 application	 in	
quality	control	laboratories.	
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